- Home
- AUNA vs XERS Comparison
AUNA vs XERS Comparison
Compare AUNA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUNA
- XERS
- Stock Information
- Founded
- AUNA 1989
- XERS 2005
- Country
- AUNA Luxembourg
- XERS United States
- Employees
- AUNA N/A
- XERS N/A
- Industry
- AUNA
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- AUNA
- XERS Health Care
- Exchange
- AUNA NYSE
- XERS Nasdaq
- Market Cap
- AUNA 521.9M
- XERS 500.2M
- IPO Year
- AUNA 2024
- XERS 2018
- Fundamental
- Price
- AUNA $7.77
- XERS $3.20
- Analyst Decision
- AUNA Strong Buy
- XERS Buy
- Analyst Count
- AUNA 4
- XERS 3
- Target Price
- AUNA $13.40
- XERS $4.87
- AVG Volume (30 Days)
- AUNA 42.3K
- XERS 1.5M
- Earning Date
- AUNA 11-19-2024
- XERS 03-05-2025
- Dividend Yield
- AUNA N/A
- XERS N/A
- EPS Growth
- AUNA N/A
- XERS N/A
- EPS
- AUNA N/A
- XERS N/A
- Revenue
- AUNA $1,168,151,825.00
- XERS $187,361,000.00
- Revenue This Year
- AUNA $17.06
- XERS $24.27
- Revenue Next Year
- AUNA $9.63
- XERS $18.57
- P/E Ratio
- AUNA N/A
- XERS N/A
- Revenue Growth
- AUNA 18.72
- XERS 22.72
- 52 Week Low
- AUNA $6.17
- XERS $1.69
- 52 Week High
- AUNA $10.85
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- AUNA N/A
- XERS 41.57
- Support Level
- AUNA N/A
- XERS $3.14
- Resistance Level
- AUNA N/A
- XERS $3.60
- Average True Range (ATR)
- AUNA 0.00
- XERS 0.17
- MACD
- AUNA 0.00
- XERS -0.03
- Stochastic Oscillator
- AUNA 0.00
- XERS 11.32
About AUNA AUNA S A
Auna SA is a healthcare provider. It operates hospitals and clinics in Mexico, Peru, and Colombia, and provides prepaid healthcare plans in Peru, and dental and vision plans in Mexico. Its network includes several healthcare network facilities, consisting of hospitals, outpatient, prevention, and wellness facilities. The company operates in the following segments; Oncosalud Peru, Healthcare services in Peru, Healthcare services in Colombia, and Healthcare services in Mexico. Key revenue is generated from Peru.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.